The Efficacy of the Combination of Naproxen and Fexofenadine (SJP-003) to Prevent or Reduce Side Effects of Receiving Multiple Travel Vaccines: A Case Report

pantea kiani, Jacqueline M. Iversen, Andrew Scholey, Joris Verster

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A considerable number of travelers receive multiple travel vaccinations before going on holiday. Here, we present a case report of a 56-year-old male traveler. On day 1, he received vaccinations against influenza, Tdab (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis), MMR (measles, mumps, and rubella), yellow fever, and cholera. On days 1,3, 5, and 7, he self-administered an oral vaccine against typhoid. Treatment comprised the combination of 220 mg naproxen and 180 mg fexofenadine (SJP-003), to be taken 4h before and 6h after the vaccinations on day 1, and every 12 h thereafter until the end of day 7. Side effects were noted daily, and their severity was scored on a scale ranging from 0 (absent) to 10 (severe). These reports revealed that, except from a slight bruising at the injection site, no side effects were experienced from day 1 to day 4. After the second dose on day 3, treatment was discontinued. Two hours after taking the typhoid vaccine on Day 5, various flu-like symptoms were reported of moderate to high severity, including fever, muscle aches (both with severity score of 8), headache (severity score 7), and nausea (severity score 6). Therefore, at 2 h after typhoid vaccination on day 5, naproxen and fexofenadine were self-administered. At 4 h thereafter, all symptoms were resolved. Treatment was continued at the 12 h schedule. On day 6 and 7, no side effects were reported. Taken together, this case study suggests that the combination of naproxen and fexofenadine was effective in preventing or reducing vaccination side effects. Therefore, more research is warranted to further evaluate the efficacy of SJP-003.

Original languageEnglish
Article number1128
Pages (from-to)1-5
JournalVaccines
Volume10
Issue number7
DOIs
Publication statusPublished - 15 Jul 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Funding

Over the past 36 months, A.S. has held research grants from Abbott Nutrition, Arla Foods, Bayer, BioRevive, DuPont, Fonterra, Kemin Foods, Nestlé, Nutricia-Danone, Verdure Sciences. He has acted as a consultant/expert advisor to Arepa Nootroptics, Bayer, Coca-Cola, Danone, Naturex, Nestlé, Pfizer, Sanofi, Sen-Jam Pharmaceutical, and has received travel/hospitality/speaker fees from Bayer, Sanofi, and Verdure Sciences. Over the past 36 months, J.C.V. has acted as a consultant/expert advisor to KNMP, Mentis, Red Bull, Sen-Jam Pharmaceutical, and Toast. J.M.I. is founder and Head of Clinical Development of Sen-Jam Pharmaceutical. P.K. has nothing to declare.

FundersFunder number
Abbott Nutrition, Arla Foods
DuPont
Bayer Fund

    Keywords

    • SJP-003
    • cholera
    • fexofenadine
    • measles
    • naproxen
    • side effects
    • travel
    • vaccination
    • willingness to vaccinate
    • yellow fever

    Fingerprint

    Dive into the research topics of 'The Efficacy of the Combination of Naproxen and Fexofenadine (SJP-003) to Prevent or Reduce Side Effects of Receiving Multiple Travel Vaccines: A Case Report'. Together they form a unique fingerprint.

    Cite this